About Avenue Therapeutics
Avenue Therapeutics is a publicly listed company based in New York (United States) founded in 2015, and was acquired by Cipla in November 2018. Formulation of tramadol HCI for the treatment of moderate to moderately severe post-operative pain. The company has 2 employees. Avenue Therapeutics has completed 1 acquisition, including Baergic Bio. Avenue Therapeutics offers products and services including AJ201, BAER-101, and IV Tramadol. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is AVENUE THERAPEUTICS, INC. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Avenue Therapeutics, a Fortress Biotech Company, is a specialty pharmaceutical company that acquiresin-licenses, develops and commercializes products principally for use in the acutehospital setting. Its initial product candidate is an intravenous (IV) formulation of tramadol HCI for the treatment of moderate to moderately severe post-operative pain. Tramadol is a synthetic dual-acting opioid and centrally acting analgesic with weak opioid agonist properties.
- Headquarters New York, United States
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website avenuetx.com
- Social LinkedIn X
- Acquired by Cipla (Nov 2018)
- Legal Name Avenue Therapeutics, Inc.
- Annual Revenue$1.4 M (USD)as on Dec 31, 2025
- Net Profit-$2.91 M (USD)75.03as on Dec 31, 2025
- EBITDA-$3.29 M (USD)70.88as on Dec 31, 2025
- Investors
- Employee Count2
- Investments & Acquisitions
- Acquired byCipla
(Nov 2018)
Products & Services of Avenue Therapeutics
Avenue Therapeutics offers a comprehensive portfolio of products and services, including AJ201, BAER-101, and IV Tramadol.
Develops treatments for neurologic diseases in the pipeline.
Innovative drug for addressing neurologic conditions effectively.
Specialty pharmaceutical for pain management in neurologic care.
Funding Insights of Avenue Therapeutics
- Total Rounds 2
- First Round $200,000
(Jan 2017)
All 2 funding rounds of Avenue Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | Post-IPO | – | – | – | |
| Jan 2017 | $200,000 | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in Avenue Therapeutics
Avenue Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cipla.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
APIs, generic drugs, and formulation services are manufactured. | 1935 | cipla.com | Mumbai, India |
Investor details for Avenue Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avenue Therapeutics
7 people are tracked at Avenue Therapeutics (3 in leadership, 4 in board & advisors); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
David Jin | Interim CFO | Leadership |
Scott A. Reines | Interim Chief Medical Officer | Leadership |
Alexandra MacLean | Chief Executive Officer And Member Board Of Directors | Leadership |
Jay Kranzler | Chairman | Board & advisors |
Curtis Oltmans | Director Board Of Directors | Board & advisors |
Neil Herskowitz | Director | Board & advisors |
Faith Charles | Director | Board & advisors |
Complete people profiles for Avenue Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avenue Therapeutics
Avenue Therapeutics is a publicly listed company on the OTC with ticker symbol ATXI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jun 2017
- Listed onNASDAQ: ATXI
- Listed entityAvenue Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS05360L4032
- Share price$0.42 (+4.88% on the day) · 2026-10-13
- Market capitalisation$1.4M
- EPS (diluted, trailing year)$-0.86
- Volume (last session)3,036
Financials of Avenue Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.4M | -$2.9M | -$3.3M |
| 2024 | -$11.7M | -$11.3M | |
| 2023 | -$10.4M | -$14.5M | |
| 2022 | -$3.5M | -$8.0M | |
| 2021 | -$3.7M | -$3.7M |
Detailed financial statements for Avenue Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avenue Therapeutics
Avenue Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Baergic Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Novel therapeutics for CNS disorders are developed and commercialized. | baergicbio.com | New York, United States | 2019 | Nov 2022 | •••• |
Complete acquisition details for Avenue Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Avenue Therapeutics
6 dated milestones of Avenue Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Avenue Therapeutics is founded.
- Funding First funding round of $200K.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Cipla.
- Acquisition Acquires Baergic Bio.
- Funding Latest funding round, Post-IPO,.
Competitors of Avenue Therapeutics
Avenue Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. |
Detailed competitors of Avenue Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avenue Therapeutics
The website of Avenue Therapeutics (avenuetx.com) receives about 2K visits a month.
- Monthly visits2K
▲ 8.3% vs previous month
Top companies in Pain Management
3 companies that operate in the same segment as Avenue Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avenue Therapeutics
Complete news archive for Avenue Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avenue Therapeutics
Avenue Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Avenue Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Avenue Therapeutics has 2 employees.
Annual revenue of Avenue Therapeutics is $1.4M as on Dec 31, 2025.
Avenue Therapeutics, a Fortress Biotech Company, is a specialty pharmaceutical company that acquiresin-licenses, develops and commercializes products principally for use in the acutehospital setting. Its initial product candidate is an intravenous (IV) formulation of tramadol HCI for the treatment of moderate to moderately severe post-operative pain. Tramadol is a synthetic dual-acting opioid and centrally acting analgesic with weak opioid agonist properties.
Avenue Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
Avenue Therapeutics offers AJ201, BAER-101, and IV Tramadol.
Yes, Avenue Therapeutics is publicly traded on OTC under the ticker symbol ATXI.
Avenue Therapeutics has made 1 acquisition, including Baergic Bio.
Avenue Therapeutics has 1 investor. Key investors include Cipla.
Avenue Therapeutics operates through Avenue Therapeutics, Inc..
Yes. Avenue Therapeutics was acquired by Cipla in November 2018.